Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
immuno-oncology
Biotech
Pfizer ties PD-1 drug to 32% cancer risk reduction in phase 3
The study fell short of a clean sweep, with Pfizer finding no effect on survival and seeing a higher rate of serious adverse events in the PD-1 arm.
Nick Paul Taylor
Apr 28, 2025 7:25am
Apollomics tags out of TYG oncology pact to cut costs
Apr 4, 2025 6:45am
BioNTech posts survival data behind bispecific's phase 3 push
Mar 28, 2025 8:00am
ImmuneOnco axes CD47 bispecific amid pipeline prioritization
Mar 26, 2025 6:21am
Pfizer to test Summit's white-hot bispecific with ADCs
Feb 24, 2025 9:17am
Incyte exits cancer pact, leaving Agenus weighing its options
Feb 11, 2025 7:55am
